What Asima treats: main uses and benefits

Asima is commonly used in therapeutic strategies for Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis, conditions presenting with persistent airflow difficulty. The primary indications are commonly established as including bronchial asthma, COPD, and pulmonary disease with a spastic bronchial component. The medication provides supportive symptomatic relief that helps ease the overall symptom load of shortness of breath and persistent cough, and may assist with maintaining functional stability over time.

This medicine is applied in contexts involving symptoms that create noticeable physiological strain, such as when managing manifestations like wheezing and the feeling of chest tightness, particularly in the treatment of bronchial asthma.

It is also relevant in clinical settings where respiratory symptoms suddenly intensify, such as during an acute exacerbation of a chronic obstructive condition. It is commonly used when short-term symptomatic assistance is needed, as it supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Airflow Restriction Symptoms The core therapeutic benefit is to address symptoms that create noticeable physiological strain, helping patients cope more steadily with symptom fluctuations and functional strain.

Regulatory References

1. Philippines FDA Verification Portal

Asima (Doxofylline) use is defined by strict regulatory guidelines detailing specific population groups who are eligible, restricted, or prohibited from using the medicine.

Populations Who Must Not Use (Contraindications)

Use of Doxofylline is strictly prohibited in individuals with known hypersensitivity to the active substance or any other methylxanthine derivatives. It is also absolutely contraindicated in patients presenting with acute myocardial infarction or hypotension. Doxofylline is likewise prohibited for use in lactating (nursing) women.

Restricted and Conditional Use

Regulatory labeling requires special caution for several populations due to potential for altered drug levels or increased sensitivity. Use with caution is advised for patients with impairment of organ function, including liver disease (hepatic dysfunction) and renal disease (renal impairment). Caution is also mandated for the elderly and for patients with cardiovascular conditions such as congestive heart failure, cardiac arrhythmias, and hypertension. Conditional use is also specified for patients with hyperthyroidism, a history of peptic ulceration, and convulsive disorders.

Age-Group Eligibility

Use is established for adults and children aged 6 years and older. In the case of pregnancy, Doxofylline should be given only if the use is clearly medically necessary, as per regulatory status. The eligibility profile is strictly defined by these absolute prohibitions and specific comorbidity-driven constraints.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Doxofylline (Asima) as stated in government regulatory prescribing information.

Formally Documented Contraindications

Co-administration of Doxofylline is strictly contraindicated with other xanthine derivatives (e.g., Theophylline). This prohibition is explicitly stated in regulatory labels due to the potential for toxic effects.

Medicines Affecting Doxofylline Exposure

Various medicines are documented to alter the concentration of Doxofylline in the body by modifying its clearance:

Interaction Type	Examples of Interacting Medicines
Increase Doxofylline Levels	Erythromycin, Cimetidine, Propranolol, Allopurinol, Anti-flu vaccine
Decrease Doxofylline Levels	Phenytoin, Other anticonvulsants

Other Significant Interaction Statements

• Sympathomimetics: Use with caution is necessary when Doxofylline is administered alongside Ephedrine and other sympathomimetic drugs, as regulatory documents note a risk of toxic synergism.
• Caffeine: The consumption of beverages and foods containing caffeine should be limited due to its potential to increase the risk of adverse effects.

Population-Specific Considerations

The clearance of Doxofylline is documented to be considerably slower in patients with Congestive Heart Failure (CHF) and is prolonged in those with Severe Liver Disease. These conditions may heighten the impact of any interactions that further reduce the drug's clearance, as noted in the official prescribing information.

Enzyme Inhibition and Bronchial Smooth Muscle Tone

Asima, containing Doxofylline, initiates its effect by acting as an inhibitor of the Phosphodiesterase (PDE) enzyme, specifically the PDE2A isoform, found in bronchial cells. This interaction prevents the breakdown of the signaling molecule cyclic adenosine monophosphate (cAMP), causing its levels to increase inside the cell. The subsequent rise in cAMP activates a biochemical cascade that ultimately reduces the concentration of intracellular calcium ( Ca^2+), leading directly to the relaxation of the bronchial smooth muscle and an increase in lumen size.

Modulation of Airway Reactivity

The mechanism of elevated intracellular cAMP extends beyond muscle relaxation, influencing the function of various inflammatory cells within the airways. The increased cAMP acts as a cellular stabilizer, which helps to dampen the activation and degranulation of these cells, thereby limiting the release of pro-inflammatory mediators. This mechanism contributes to the attenuation of bronchial reactivity by stabilizing cell function against stimuli. Notably, Doxofylline achieves this without relying significantly on adenosine receptor antagonism, a defining difference in its pharmacological profile.

The administration of Asima (Doxofylline) involves distinct protocols for oral maintenance use and intravenous use for acute episodes.

Administration Routes and Dosing

Doxofylline is provided in oral forms (tablets, solution) for long-term therapy and as an injectable solution for intravenous (IV) administration. The standard adult oral dosing regimen is typically 400 mg taken two to three times daily, though the dose is sometimes adjusted up to a maximum of 1200 mg per day. For short-term management of acute symptoms, the medicine is used intravenously as a 200 mg injection.

Frequency and Procedural Conditions

Oral maintenance doses are structured on a twice or thrice daily schedule. When used intravenously, the 200 mg dose is administered by slow injection over a duration of 15 to 20 minutes and may be repeated after a 12-hour interval. The oral form is sometimes taken with food to support tolerance, and it is noted that the medicine must not be used concurrently with other xanthine derivatives, including products containing caffeine.

Population-Specific Rules

Specific modifications to the standard adult dose exist for particular patient groups. Older adults are often administered a reduced dose, typically 200 mg two or three times daily. Furthermore, the dose for pediatric patients over 6 years old is calculated based on weight, with a maximum limit of 18 mg/kg per day. A reduced dose may also be necessary for patients with impaired hepatic or renal function.

Research Evidence: Overview of Studies for Asima (Doxofylline)

Evidence for Use in Bronchial Asthma

The research on Asima has primarily been conducted through randomized controlled trials (RCTs), which are designed to compare the medicine against other active treatments, such as older xanthine medicines like theophylline. Research explored comparisons against a placebo and observed responses over defined time intervals and examined temporary physiological imbalance.

Studies have included populations of adults and adolescents, and some research was conducted in pediatric patients with stable asthma. The main outcomes research examined included objective measures of lung function, such as the forced expiratory volume in 1 second ( FEV1), as well as patient-reported outcomes describing perceived discomfort, such as the severity of wheezing and chest tightness.

Research describes patterns observed in the studies, where changes in FEV1 measurements and symptom reporting were monitored. Peer-reviewed meta-analyses suggest the evidence for these patterns is relatively consistent when compared against placebo or theophylline. However, the available evidence is limited regarding the medicine's effect profile in large-scale trials when directly compared against the most current, first-line inhaled therapies for asthma.

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

The research base for Asima in COPD and chronic bronchitis includes randomized controlled trials and systematic reviews. These studies explored short-term symptom changes and examined temporary physiological imbalance. Asima was studied as an adjunctive agent explored alongside maximal inhalation therapy.

Research examined outcomes related to physical discomfort and functional outcomes reflecting daily functioning or activity level, such as exercise capacity (e.g., the 6-minute walking distance). Studies monitored short-term changes in dyspnea (shortness of breath) and health status scales. Findings describe patterns observed in the studies, including changes in FEV1 over short defined time intervals. However, data show patterns related to functional capacity changes were mixed when compared against some other active bronchodilator agents.

The research base is currently not reflected in major international clinical practice guidelines for COPD, which highlights an existing research gap.

Study Durations and Long-Term Follow-up

Most of the primary clinical trials for Asima were conducted over short-term follow-up durations, typically lasting only a few weeks to a few months. Research has explored short-term symptom changes, but there is limited information for long-term outcomes.

Common questions about Asima (FAQ)

Q: How long does Doxofylline stay in your system after you stop taking it?

Official information regarding Doxofylline’s processing by the body indicates that the elimination half-life is typically 8 to 10 hours during oral maintenance therapy. The half-life is the time it takes for half of the drug to be cleared from the bloodstream. According to prescribing information, the drug's clearance may be prolonged in certain patient groups, including those with liver disease or congestive heart failure.

Q: Is Asima used for the common cold or flu-related coughs?

Regulatory documents state that Doxofylline is indicated as a bronchodilator for the management of reversible airway obstruction. The medicine is indicated for managing conditions such as bronchial asthma and chronic obstructive pulmonary disease (COPD). It is not specifically indicated for treating symptoms associated with the common cold or the flu.

Q: What is the main difference between Asima and Theophylline?

According to official product information, Doxofylline is a newer generation xanthine derivative that differs structurally from Theophylline. Pharmacologically, Doxofylline has a decreased affinity for adenosine receptors. This difference in action may be associated with the characteristics described in its safety profile.

Q: What are the signs of a Doxofylline overdose?

Official safety information recognizes the potential for serious adverse reactions in the context of over-exposure. These documented critical events include convulsions (seizures) and severe cardiac arrhythmias, which are serious irregularities of the heart rhythm.

Q: How quickly does Asima start working after I take the oral tablet?

Studies indicate that after taking an oral dose of Doxofylline, the peak concentration of the medicine in the bloodstream is typically reached after approximately one hour. The time it takes to reach peak levels is a pharmacokinetic characteristic described in the official information.

Q: Is Doxofylline safe to use during pregnancy?

Official prescribing information states that Doxofylline is not recommended for use during pregnancy. Use in pregnancy is subject to medical necessity. The official prescribing information indicates that Doxofylline should only be administered if the clinical need is clear.

Q: Can Doxofylline be used to treat pneumonia?

Official documents define the uses of Doxofylline as being limited to managing conditions involving reversible airway obstruction, such as bronchial asthma and COPD. It is not indicated for the specific treatment of pneumonia.

Q: What is the dose for children under 6 years old?

Regulatory information specifies age-group eligibility for Doxofylline. Dosing is established and recommended for children who are 6 years of age and older. Doxofylline is not recommended for use in children who are under 6 years old.

How to Store and Dispose of Asima

Official regulatory documents define strict requirements for the storage, handling, and disposal of medicinal products like Asima to ensure quality and safety.

Storage and Protection

Requirement	Official Mandate
Temperature	Store below the maximum labeled temperature (e.g., 30mathrmC or 25mathrmC) or within the required refrigerated range (2mathrmC - 8mathrmC) if specified.
Environmental	Protect from both moisture and light by keeping the medicine in its original package and container.
Child Safety	As with all medicines, it must be stored out of the sight and reach of children.
In-Use Stability	If applicable, the product must be used within a defined period (e.g., 28 days) after the container is first opened or reconstituted.

Disposal Rules

Official disposal instructions require that expired or unused medicine be returned to a pharmacy or authorized collection program. Disposal into household trash, sinks, or toilets is strictly prohibited to prevent environmental contamination.